Mainz, December 20, 2013 – – TRON is whishing all of its partners and friends happy holidays and a successful New Year 2014. The TRON labs and offices are closed December 23 through January 1.
Mainz, Germany, December 12, 2013 – A new study by TRON researchers has affirmed the role of the placenta-specific gene PLAC1 as a promising candidate for targeted breast cancer therapies. The findings by Wagner et al. have been published in the December issue of BMC Cancer.
Mainz, December 12, 2013 – “The Genetics of Melanoma: Searching for New Therapeutic Targets” with Prof. Yardena Samuels – Weizmann Institute of Science, Rehovot, Israel
Mainz, December 3, 2013 – “RIG-I ligand therapies” with Prof. Dr. med. Gunther Hartmann – University Medical Center Bonn, Germany
Mainz, November 22, 2013 – As part of the state of Rhineland-Palatinate’s health research and technology exhibit at MEDICA, November 20-23, 2013 in Düsseldorf, Germany, TRON is presenting its research, mission and service offerings.
Mainz, November 12, 2013 – Dr. Sebastian Kreiter, head of the TRON Immunotherapy Development Center, will present about novel approaches to molecular vaccines as part of the ESMO Symposium on Immuno-Oncology in Geneva.
Mainz, Germany, October 23, 2013 – As part of the „Ci3 Schaufenster“ event series, TRON invites the Ci3 partners as well as the interested public to an information evening on November 13 about the structure and work of TRON. A special focus will be put on the role of next-generation sequencing in biomarker identification and
Mainz, October 17, 2013 – The Regulatory Research Group of the Association for Cancer Immunotherapy (CIMT-RRG) has published a blueprint for the development of “actively personalized” vaccines (APVACs). The proposal, published in the October issue of Nature Biotechnology, outlines how APVACs may be pursued within the existing regulatory framework of the European Union (EU).
Mainz, Germany, October 9, 2013 – TRON researchers together with scientists from the University Medical Center Mainz have tracked down the molecular mechanisms leading to one of the most common types of blood cancer, a disease called core binding factor acute myeloid leukaemia (CBF-AML). The results are now published in the journal EMBO Molecular Medicine.
Mainz, October 7, 2013 – At BIOTECHNICA 2013 in Hannover (October 8-10), TRON researchers Dr. Cedrik Britten and Dr. Valesca Boisguérin will present methods and platforms for personalized cancer diagnostics and therapeutics that are researched and developed at TRON.
Heidelberg, September 23, 2013 – At the New Cancer Targets Conference in Heidelberg, TRON founder and scientific director Ugur Sahin will address the path towards individualized immunotherapy. Sahin is one of 30 international speakers invited by the National Center for Tumor Diseases (NCT) Heidelberg.
Mainz, Germany, September 17, 2013 – Today, partners of the BMBF funded Cluster for Individualized ImmuneIntervention present their ongoing projects at Schloss Biebrich in Wiesbaden. The day-long event offers cluster partners the opportunity to network and provide project updates. As a Ci3 partner, TRON will participate with several short talks, posters and an information booth.